Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients.
Anthony Joseph DixonAthanassios KyrgidisHoward K SteinmanJohn B DixonMichael J SladdenClaus GarbeAimillios LallasChristopher B ZacharyUlrike LeiterHarvey Ronald SmithAlexander NirenbergChristos C ZouboulisCaterina LongoGiuseppe ArgenzianoZoi ApallaCatalin PopescuThrasyvoulos TzellosStuart AndersonLena NanzLloyd CleaverJ Meirion ThomasPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
is likely more appropriate. BAUSSS provides a more accurate melanoma-specific mortality risk assessment for patients without burdening them with added surgery, hospitalization, costs or morbidity risk.
Keyphrases
- sentinel lymph node
- risk assessment
- end stage renal disease
- cardiovascular events
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early stage
- lymph node
- minimally invasive
- risk factors
- neoadjuvant chemotherapy
- type diabetes
- squamous cell carcinoma
- coronary artery disease
- ultrasound guided
- skin cancer
- acute coronary syndrome
- locally advanced